KDMN
Kadmon Holdings, Inc. [KDMN] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
KDMN Stock Summary
In the News
KDMN Financial details
Company Rating
Neutral
Market Cap
0
Income
-120.2M
Revenue
16.08M
Book val./share
0.08
Cash/share
1.5
Dividend
-
Dividend %
-
Employees
127
Optionable
No
Shortable
Yes
Earnings
04 Nov 2021
P/E
-14.5
Forward P/E
-
PEG
-2.78
P/S
-
P/B
13.61
P/C
6.33
P/FCF
-
Quick Ratio
4.58
Current Ratio
4.66
Debt / Equity
18.61
LT Debt / Equity
18.27
-
-
EPS (TTM)
-0.7
EPS next Y
-
EPS next Q
-
EPS this Y
43.48%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-40.46%
Revenue last 5Y
-20.47%
Revenue Q/Q
7364.97%
EPS Q/Q
5.56%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
90.38%
Inst Trans
0.95%
ROA
-67%
ROE
-77%
ROC
-0.77%
Gross Margin
76%
Oper. Margin
-1234%
Profit Margin
-1314%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
9.48-9.495
52W High
+5.56%
52W Low
+5.56%
RSI
-
Rel Volume
1.04
Avg Volume
10.03M
Volume
10.42M
Perf Week
0%
Perf Month
0%
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
1.12312
-
-
Volatility
0%, 0%
Prev Close
0%
Price
9.5
Change
0.21%
KDMN Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2020-12-31
| Metric | History | 2016-12-31 | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.1 | 0.21 | 0.01 | 0.04 | 0.05 | |
| Net income per share | -8.82 | -1.39 | -0.56 | -0.46 | -0.66 | |
| Operating cash flow per share | -2.24 | -1.12 | -0.73 | -0.61 | -0.53 | |
| Free cash flow per share | -2.26 | -1.12 | -0.74 | -0.61 | -0.53 | |
| Cash per share | 1.52 | 1.18 | 0.97 | 1.37 | 0.81 | |
| Book value per share | -1.06 | 0.03 | 0.91 | 1.25 | 0.7 | |
| Tangible book value per share | -1.22 | -0.03 | 0.87 | 1.23 | 0.68 | |
| Share holders equity per share | -1.06 | 0.03 | 0.91 | 1.25 | 0.7 | |
| Interest debt per share | 4.01 | 0.65 | 0.32 | 0.05 | 0.14 | |
| Market cap | 126.66M | 207.81M | 203.03M | 599.36M | 689.9M | |
| Enterprise value | 121.14M | 174M | 135.77M | 483.49M | 638.33M | |
| P/E ratio | -0.61 | -2.6 | -3.74 | -9.77 | -6.33 | |
| Price to sales ratio | 4.86 | 16.94 | 145.43 | 117.64 | 83.24 | |
| POCF ratio | -2.39 | -3.24 | -2.85 | -7.49 | -7.88 | |
| PFCF ratio | -2.37 | -3.22 | -2.82 | -7.44 | -7.84 | |
| P/B Ratio | -5.03 | 118.21 | 2.3 | 3.62 | 5.95 | |
| PTB ratio | -5.03 | 118.21 | 2.3 | 3.62 | 5.95 | |
| EV to sales | 4.65 | 14.19 | 97.25 | 94.89 | 77.02 | |
| Enterprise value over EBITDA | -0.96 | -2.34 | -2.73 | -8.52 | -5.94 | |
| EV to operating cash flow | -2.29 | -2.71 | -1.91 | -6.04 | -7.29 | |
| EV to free cash flow | -2.26 | -2.69 | -1.88 | -6 | -7.26 | |
| Earnings yield | -1.65 | -0.38 | -0.27 | -0.1 | -0.16 | |
| Free cash flow yield | -0.42 | -0.31 | -0.36 | -0.13 | -0.13 | |
| Debt to equity | -1.21 | 19.17 | 0.31 | 0.02 | 0.2 | |
| Debt to assets | 0.49 | 0.4 | 0.19 | 0.02 | 0.14 | |
| Net debt to EBITDA | 0.04 | 0.45 | 1.35 | 2.04 | 0.48 | |
| Current ratio | 1.63 | 1.24 | 4.12 | 6.42 | 4.66 | |
| Interest coverage | -1.86 | -18.43 | -24.09 | -31.63 | -4.87K | |
| Income quality | 0.25 | 0.8 | 1.31 | 1.3 | 0.8 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 4.06 | 3.02 | 26.97 | 7.15 | 0 | |
| Research and developement to revenue | 1.38 | 3.32 | 35.08 | 11.08 | 7.89 | |
| Intangibles to total assets | 0.06 | 0.04 | 0.02 | 0.02 | 0.02 | |
| Capex to operating cash flow | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Capex to revenue | -0.02 | -0.04 | -0.62 | -0.1 | -0.05 | |
| Capex to depreciation | -0.03 | -0.26 | -0.56 | -0.29 | -0.27 | |
| Stock based compensation to revenue | 1.81 | 1.01 | 7.44 | 1.41 | 1.13 | |
| Graham number | 14.53 | 0.98 | 3.37 | 3.62 | 3.21 | |
| ROIC | -22.23 | -1.93 | -0.73 | -0.46 | -0.64 | |
| Return on tangible assets | -3.54 | -1 | -0.38 | -0.29 | -0.68 | |
| Graham Net | -2.1 | -0.23 | 0.41 | 1.01 | 0.53 | |
| Working capital | 15.54M | 13.37M | 74.92M | 155.86M | 107.83M | |
| Tangible asset value | -28.77M | -1.82M | 84.83M | 162.16M | 112.44M | |
| Net current asset value | -47.46M | -11.78M | 42.69M | 135.54M | 90.61M | |
| Invested capital | -1.21 | 19.17 | 0.31 | 0.02 | 0.2 | |
| Average receivables | 2.3M | 1.2M | 1.44M | 1.32M | 824.5K | |
| Average payables | 6.1M | 7.15M | 9M | 9.51M | 9.99M | |
| Average inventory | 2.71M | 1.08M | 563K | 782.5K | 371K | |
| Days sales outstanding | 16.95 | 35.3 | 441.87 | 68.34 | 30.61 | |
| Days payables outstanding | 593.81 | 978.87 | 5.34K | 2.56K | 1.99K | |
| Days of inventory on hand | 183.91 | 24.57 | 495.05 | 181.23 | 18.61 | |
| Receivables turnover | 21.53 | 10.34 | 0.83 | 5.34 | 11.93 | |
| Payables turnover | 0.61 | 0.37 | 0.07 | 0.14 | 0.18 | |
| Inventory turnover | 1.98 | 14.86 | 0.74 | 2.01 | 19.62 | |
| ROE | 8.29 | -45.38 | -0.61 | -0.37 | -0.94 | |
| Capex per share | -0.02 | -0.01 | -0.01 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2021-09-30 for Q3
| Metric | History | 2020-09-30 | 2020-12-31 | 2021-03-31 | 2021-06-30 | 2021-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0.08 | |
| Net income per share | -0.15 | -0.16 | -0.17 | -0.18 | -0.19 | |
| Operating cash flow per share | -0.14 | -0.16 | -0.16 | -0.15 | -0.16 | |
| Free cash flow per share | -0.14 | -0.16 | -0.16 | -0.15 | -0.16 | |
| Cash per share | 0.94 | 0.79 | 1.78 | 1.64 | 1.5 | |
| Book value per share | 0.83 | 0.68 | 0.34 | 0.19 | 0.08 | |
| Tangible book value per share | 0.81 | 0.66 | 0.32 | 0.17 | 0.06 | |
| Share holders equity per share | 0.83 | 0.68 | 0.34 | 0.19 | 0.08 | |
| Interest debt per share | 0.14 | 0.13 | 1.49 | 1.47 | 1.46 | |
| Market cap | 663.7M | 703.91M | 667.87M | 665.51M | 1.51B | |
| Enterprise value | 581.58M | 652.34M | 790.23M | 854.34M | 1.69B | |
| P/E ratio | -6.74 | -6.32 | -5.88 | -5.48 | -11.23 | |
| Price to sales ratio | 1.35K | 1.14K | 1.19K | 3.38K | 102.73 | |
| POCF ratio | -28.1 | -26.66 | -24.26 | -26.58 | -54.32 | |
| PFCF ratio | -27.95 | -26.51 | -24.08 | -26.54 | -54.32 | |
| P/B Ratio | 4.7 | 6.07 | 11.28 | 19.89 | 112.47 | |
| PTB ratio | 4.7 | 6.07 | 11.28 | 19.89 | 112.47 | |
| EV to sales | 1.19K | 1.06K | 1.4K | 4.34K | 115.04 | |
| Enterprise value over EBITDA | -24.05 | -23.59 | -29.47 | -30.88 | -54.57 | |
| EV to operating cash flow | -24.63 | -24.71 | -28.7 | -34.12 | -60.83 | |
| EV to free cash flow | -24.49 | -24.57 | -28.49 | -34.06 | -60.83 | |
| Earnings yield | -0.04 | -0.04 | -0.04 | -0.05 | -0.02 | |
| Free cash flow yield | -0.04 | -0.04 | -0.04 | -0.04 | -0.02 | |
| Debt to equity | 0.17 | 0.2 | 4.3 | 7.49 | 18.61 | |
| Debt to assets | 0.13 | 0.14 | 0.76 | 0.81 | 0.82 | |
| Net debt to EBITDA | 3.4 | 1.86 | -4.56 | -6.83 | -5.84 | |
| Current ratio | 5.76 | 4.66 | 11 | 9.46 | 6.32 | |
| Interest coverage | -3.5K | -3.9K | -22.3 | -12.81 | -10.59 | |
| Income quality | 0.96 | 0.95 | 0.97 | 0.83 | 0.83 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 35.24 | 30.46 | 27.13 | 94.04 | 1.28 | |
| Intangibles to total assets | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | |
| Capex to operating cash flow | 0.01 | 0.01 | 0.01 | 0 | 0 | |
| Capex to revenue | -0.27 | -0.25 | -0.36 | -0.22 | 0 | |
| Capex to depreciation | -0.31 | -0.4 | -0.6 | -0.24 | 0 | |
| Stock based compensation to revenue | 5.01 | 3.66 | 6.52 | 20.04 | 0.24 | |
| Graham number | 1.65 | 1.59 | 1.13 | 0.88 | 0.58 | |
| ROIC | -0.17 | -0.2 | -0.08 | -0.12 | -0.08 | |
| Return on tangible assets | -0.13 | -0.18 | -0.09 | -0.1 | -0.11 | |
| Graham Net | 0.66 | 0.52 | 0.18 | 0.03 | -0.09 | |
| Working capital | 134.18M | 107.83M | 282.45M | 256.44M | 237.19M | |
| Tangible asset value | 137.78M | 112.44M | 55.62M | 29.88M | 10.43M | |
| Net current asset value | 114.71M | 90.61M | 34.8M | 9.93M | -8.5M | |
| Invested capital | 0.17 | 0.2 | 4.3 | 7.49 | 18.61 | |
| Average receivables | 384.5K | 534K | 1.11M | 1.53M | 9.76M | |
| Average payables | 11.89M | 11.52M | 11.6M | 11.42M | 15.96M | |
| Average inventory | 72K | 65K | 62K | 17K | 17K | |
| Days sales outstanding | 68.51 | 101.71 | 242.82 | 704.92 | 110.01 | |
| Days payables outstanding | 3.01K | 4.05K | 11.51K | 86.39K | 2.99K | |
| Days of inventory on hand | 6.96 | 37.78 | 20.63 | 98.18 | 3.08 | |
| Receivables turnover | 1.31 | 0.88 | 0.37 | 0.13 | 0.82 | |
| Payables turnover | 0.03 | 0.02 | 0.01 | 0 | 0.03 | |
| Inventory turnover | 12.93 | 2.38 | 4.36 | 0.92 | 29.23 | |
| ROE | -0.17 | -0.24 | -0.48 | -0.91 | -2.5 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
KDMN Frequently Asked Questions
What is Kadmon Holdings, Inc. stock symbol ?
Kadmon Holdings, Inc. is a US stock , located in New york city of New york and trading under the symbol KDMN
What is Kadmon Holdings, Inc. stock quote today ?
Kadmon Holdings, Inc. stock price is $9.5 today.
Is Kadmon Holdings, Inc. stock public?
Yes, Kadmon Holdings, Inc. is a publicly traded company.
Company Profile
- Volume Average 10.03M
- Employee 127
- CEO Dr. Harlan Waksal
- Headquarters New York City,NEW YORK,US
- IPO Date 2016-07-27
-
Website
http://www.kadmon.com 
Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include KD025, an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical trial for the treatment of chronic graft-versus-host and fibrotic diseases; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; ribavirin, a nucleoside Inhibitor to treat hepatitis; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. The company was founded in 2010 and is headquartered in New York, New York.
